Oncology Imaging Lead: Biomarker Strategy & Trials

Regeneron Pharmaceuticals, Inc; Cambourne; Remote; GBP 80,000 - 140,000; Full time

Job summary

Regeneron Pharmaceuticals, Inc. seeks an Oncology Imaging Scientific Lead to drive imaging biomarker strategy in early and late phase studies. You will lead multimodality imaging endpoints, design protocols, and work with cross-functional teams to ensure robust imaging data and interpretation.

You'll collaborate with regulatory bodies and external partners, oversee image analysis, and help advance novel PET/immuno-PET biomarkers within the clinical development pipeline.

Qualifications

• Experience implementing central efficacy assessment using RECIST 1.1, PCWG3, Lugano, IMWG in oncology trials.
• Leadership in applying imaging as a quantitative endpoint in oncology studies.
• Strong written and verbal communication and organizational skills.
• Experience with regulatory agencies and inspections is preferred.

Responsibilities

• Lead imaging biomarker strategy to inform and advance the Regeneron pipeline.
• Design and implement multimodality imaging measures as trial endpoints.
• Collaborate with clinical teams to ensure imaging strategy, protocols and analysis plans.
• Coordinate with imaging operations and CROs to ensure data integrity of imaging components.
• Serve as Imaging Scientific Lead for trials focused on novel biomarkers.
• Interact with regulatory agencies and ethics committees for approvals.
• Design and implement PET and immuno-PET imaging biomarkers in trials.
• Oversee image analysis and generation of study reports and publications.
• Collaborate with external partners to advance translational imaging strategies.

Skills

Leadership

Imaging biomarkers

Multimodality imaging

PET/CT imaging

Regulatory liaison

Clinical trial imaging strategy

CRO oversight

Study protocol development

Education

Doctorate in a relevant field

Job description

Regeneron Pharmaceuticals, Inc. seeks an Oncology Imaging Scientific Lead to drive imaging biomarker strategy in early and late phase studies. You will lead multimodality imaging endpoints, design protocols, and work with cross-functional teams to ensure robust imaging data and interpretation.

You'll collaborate with regulatory bodies and external partners, oversee image analysis, and help advance novel PET/immuno-PET biomarkers within the clinical development pipeline.